DXCM
Price
$79.54
Change
-$0.50 (-0.62%)
Updated
Dec 23 closing price
44 days until earnings call
IRMD
Price
$54.07
Change
-$0.58 (-1.06%)
Updated
Dec 23 closing price
44 days until earnings call
Ad is loading...

DXCM vs IRMD

Header iconDXCM vs IRMD Comparison
Open Charts DXCM vs IRMDBanner chart's image
DexCom
Price$79.54
Change-$0.50 (-0.62%)
Volume$2.39M
CapitalizationN/A
iRadimed
Price$54.07
Change-$0.58 (-1.06%)
Volume$28.47K
CapitalizationN/A
DXCM vs IRMD Comparison Chart
Loading...
DXCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DXCM vs. IRMD commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DXCM is a Buy and IRMD is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Dec 24, 2024
Stock price -- (DXCM: $79.54 vs. IRMD: $54.07)
Brand notoriety: DXCM and IRMD are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: DXCM: 56% vs. IRMD: 67%
Market capitalization -- DXCM: $53.47B vs. IRMD: $557.04M
DXCM [@Medical Specialties] is valued at $53.47B. IRMD’s [@Medical Specialties] market capitalization is $557.04M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DXCM’s FA Score shows that 1 FA rating(s) are green whileIRMD’s FA Score has 2 green FA rating(s).

  • DXCM’s FA Score: 1 green, 4 red.
  • IRMD’s FA Score: 2 green, 3 red.
According to our system of comparison, IRMD is a better buy in the long-term than DXCM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DXCM’s TA Score shows that 5 TA indicator(s) are bullish while IRMD’s TA Score has 3 bullish TA indicator(s).

  • DXCM’s TA Score: 5 bullish, 3 bearish.
  • IRMD’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, DXCM is a better buy in the short-term than IRMD.

Price Growth

DXCM (@Medical Specialties) experienced а +4.10% price change this week, while IRMD (@Medical Specialties) price change was +1.67% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -0.30%. For the same industry, the average monthly price growth was +0.69%, and the average quarterly price growth was +2.47%.

Reported Earning Dates

DXCM is expected to report earnings on Feb 06, 2025.

IRMD is expected to report earnings on Feb 06, 2025.

Industries' Descriptions

@Medical Specialties (-0.30% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DXCM($53.5B) has a higher market cap than IRMD($557M). DXCM has higher P/E ratio than IRMD: DXCM (106.11) vs IRMD (31.84). IRMD YTD gains are higher at: 15.011 vs. DXCM (-35.901). DXCM has higher annual earnings (EBITDA): 917M vs. IRMD (20.8M). DXCM has more cash in the bank: 2.72B vs. IRMD (49.8M). IRMD has less debt than DXCM: IRMD (2.04M) vs DXCM (2.59B). DXCM has higher revenues than IRMD: DXCM (3.62B) vs IRMD (65.6M).
DXCMIRMDDXCM / IRMD
Capitalization53.5B557M9,605%
EBITDA917M20.8M4,409%
Gain YTD-35.90115.011-239%
P/E Ratio106.1131.84333%
Revenue3.62B65.6M5,521%
Total Cash2.72B49.8M5,470%
Total Debt2.59B2.04M126,970%
FUNDAMENTALS RATINGS
DXCM vs IRMD: Fundamental Ratings
DXCM
IRMD
OUTLOOK RATING
1..100
1469
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
15
Undervalued
PROFIT vs RISK RATING
1..100
7323
SMR RATING
1..100
2940
PRICE GROWTH RATING
1..100
5842
P/E GROWTH RATING
1..100
9341
SEASONALITY SCORE
1..100
n/a33

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IRMD's Valuation (15) in the Medical Specialties industry is somewhat better than the same rating for DXCM (78). This means that IRMD’s stock grew somewhat faster than DXCM’s over the last 12 months.

IRMD's Profit vs Risk Rating (23) in the Medical Specialties industry is somewhat better than the same rating for DXCM (73). This means that IRMD’s stock grew somewhat faster than DXCM’s over the last 12 months.

DXCM's SMR Rating (29) in the Medical Specialties industry is in the same range as IRMD (40). This means that DXCM’s stock grew similarly to IRMD’s over the last 12 months.

IRMD's Price Growth Rating (42) in the Medical Specialties industry is in the same range as DXCM (58). This means that IRMD’s stock grew similarly to DXCM’s over the last 12 months.

IRMD's P/E Growth Rating (41) in the Medical Specialties industry is somewhat better than the same rating for DXCM (93). This means that IRMD’s stock grew somewhat faster than DXCM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DXCMIRMD
RSI
ODDS (%)
Bearish Trend 1 day ago
70%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
73%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
55%
MACD
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
56%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
74%
Bullish Trend 5 days ago
74%
Declines
ODDS (%)
Bearish Trend 9 days ago
70%
Bearish Trend 7 days ago
59%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
N/A
View a ticker or compare two or three
Ad is loading...
DXCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BDOKX10.190.08
+0.79%
iShares MSCI Total Intl Idx K
HEMRX9.280.06
+0.65%
Janus Henderson Emerging Markets N
MFRHX57.890.30
+0.52%
MFS Research R3
ULPIX143.05N/A
N/A
ProFunds UltraBull Inv
RSEIX15.05N/A
N/A
Royce Small-Cap Special Equity Instl

DXCM and

Correlation & Price change

A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with CERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then CERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXCM
1D Price
Change %
DXCM100%
-0.62%
CERS - DXCM
42%
Loosely correlated
N/A
IRMD - DXCM
34%
Loosely correlated
-1.06%
AORT - DXCM
33%
Loosely correlated
-0.70%
ACRS - DXCM
33%
Loosely correlated
+6.25%
COO - DXCM
32%
Poorly correlated
-0.98%
More

IRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, IRMD has been loosely correlated with LUNG. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if IRMD jumps, then LUNG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IRMD
1D Price
Change %
IRMD100%
-1.06%
LUNG - IRMD
42%
Loosely correlated
+1.79%
HBIO - IRMD
40%
Loosely correlated
-0.47%
GKOS - IRMD
38%
Loosely correlated
-1.67%
CRL - IRMD
38%
Loosely correlated
-0.20%
BLFS - IRMD
38%
Loosely correlated
-3.69%
More